Table 2.

Summary of AEs occurring in ≥20% of all patients, AEs of grade ≥3 occurring in ≥5% of all patients, and SAEs for each cohort

	AZD4547 dose
	Part A					Part B
	40 mg bid (N = 3)	80 mg bid (N = 6)	120 mg bid (N = 6)	160 mg qd (N = 15)	Total Part A (N = 30)	80 mg bid (N = 4)
Patients with AE of any grade, n (%)	3 (100)	6 (100)	6 (100)	14 (93.3)	29 (97.6)	4 (100)
Dysgeusia	0 (0)	2 (33.3)	5 (83.3)	7 (50.0)	14 (46.7)	3 (75.0)
Diarrhoea	0 (0)	2 (33.3)	5 (83.3)	5 (33.3)	12 (40.0)	1 (25.0)
Stomatitis	1 (33.3)	4 (66.7)	4 (66.7)	3 (20.0)	12 (40.0)	2 (50.0)
Hyperphosphataemia	0 (0)	1 (16.7)	3 (50.0)	7 (50.0)	11 (36.7)	2 (50.0)
Dry mouth	0 (0)	3 (50.0)	2 (33.3)	5 (33.3)	10 (33.3)	2 (50.0)
Dry skin	1 (33.3)	2 (33.3)	2 (33.3)	4 (26.7)	9 (30.0)	0 (0)
Nausea	1 (33.3)	2 (33.3)	1 (16.7)	4 (26.7)	8 (26.7)	2 (50.0)
Detachment of retinal pigment epithelium	0 (0)	0 (0)	0 (0)	7 (50.0)	7 (23.3)	1 (25.0)
Vomiting	0 (0)	2 (33.3)	2 (33.3)	2 (13.3)	6 (20.0)	1 (25.0)
Malaise	0 (0)	2 (33.3)	2 (33.3)	2 (13.3)	6 (20.0)	1 (25.0)
Decreased appetite	1 (33.3)	1 (16.7)	1 (16.7)	2 (13.3)	6 (20.0)	2 (50.0)
Patients with CTCAE grade ≥3 event, n (%)	0 (0)	3 (50.0)	0 (0)	0 (0)	3 (10.0)	3 (75.0)
Neutropenia	0 (0)	2 (33.3)	0 (0)	0 (0)	2 (6.7)	1 (25.0)
Nausea	0 (0)	2 (33.3)	0 (0)	0 (0)	2 (6.7)	0 (0)
Decreased appetite	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (3.3)	2 (50.0)
Stomatitis	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (3.3)	0 (0)
Pneumonia	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.3)	1 (25.0)
Increased alanine aminotransferase	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (3.3)	0 (0)
Decreased appetite	0 (0)	1 (16.7)	0 (0)	0 (0)	1 (3.3)	0 (0)
Hypoglycaemia	0 (0)	0 (0)	0 (0)	0 (0)	1 (3.3)	1 (25.0)
Patients with SAE grade ≥3 event, n (%)	0 (0)	0 (0)	2 (33.3)	0 (0)	2 (6.7)	1 (25.0)
Nausea	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.3)	0 (0)
Stomatitis	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.3)	0 (0)
Decreased appetite	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.3)	1 (25.0)

SAE serious adverse event